Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069780 | 0.80 | KDM4E (0.49) | KDM4EHIF1ATDP1TSHRG6PD | |
| SCHEMBL30367223 | 0.80 | KDM4E (0.48) | KDM4EHIF1ATDP1TSHRG6PD | |
| SCHEMBL31013216 | 0.79 | KDM4E (0.63) | KDM4EHIF1ATDP1TSHRG6PD | |
| SCHEMBL987976 | 0.78 | HPGD (0.43) | KDM4EKMOSMN1; SMN2 | |
| SCHEMBL29589123 | 0.78 | GPR35 (0.60) | GPR35KDM4ETDP1TSHRCYP1A2 | |
| SCHEMBL71886 | 0.78 | GPR35 (0.60) | GPR35KDM4ETDP1TSHRCYP1A2 | |
| SCHEMBL28745129 | 0.76 | GPR35 (0.58) | GPR35KDM4ETDP1TSHRCYP1A2 | |
| SCHEMBL29011362 | 0.75 | CA12 (0.47) | KDM4EHIF1ATDP1G6PDCASP7 | |
| SCHEMBL19064516 | 0.75 | KDM4E (0.43) | KDM4EHIF1ATDP1TSHRCYP1A2 | |
| SCHEMBL11804177 | 0.75 | GPR35 (0.49) | GPR35KDM4EHIF1ATSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069562-A1 | Process for the preparation of alfuzosin | AUROBINDO PHARMA LTD (IN) | 2009-03-12 | — | — | US | claimed |
| US-10695435-B2 | Composition comprising a polymeric reagent | NEKTAR THERAPEUTICS (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190046651-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-10130720-B2 | Composition comprising a polymeric reagent | NEKTAR THERAPEUTICS (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170348426-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2017-12-07 | — | — | US | disclosed |
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| WO-2010056919-A2 | EFLORNITHINE PRODRUGS, CONJUGATES AND SALTS, AND METHODS OF USE THEREOF | KYPHIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-6818787-B2 | FOR THERAPY AND PROPHYLAXIS OF EPILEPSY, DEPRESSION, ANXIETY, PSYCHOSIS, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, PANIC, PAIN, INFLAMMATORY DISEASE, INSOMNIA, GASTROINTESTINAL DISORDERS | XENOPORT, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | GPR35 453/4885KDM4E 1341/4885HIF1A 1245/4885 |
| US-20090069562-A1 | Process for the preparation of alfuzosin | QDPR, OPRD1, OPRK1 | GPR35 3561/4885KDM4E 716/4885HIF1A 1746/4885 |
| US-10130720-B2 | Composition comprising a polymeric reagent | CD44, FCGRT, C9 | GPR35 2851/4885KDM4E 3938/4885HIF1A 3257/4885 |
| US-20190046651-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | CD44, FCGRT, C9 | GPR35 2851/4885KDM4E 3938/4885HIF1A 3257/4885 |
| US-20170348426-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | CD44, FCGRT, C9 | GPR35 2851/4885KDM4E 3938/4885HIF1A 3257/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | GPR35 453/4885KDM4E 1341/4885HIF1A 1245/4885 |
| US-10695435-B2 | Composition comprising a polymeric reagent | CD44, FCGRT, C9 | GPR35 2851/4885KDM4E 3938/4885HIF1A 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.